A Single Dose, Randomized, Open-Label, Parallel Group Study Comparing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ticagrelor in Haemodialysis Patients to Subjects With Normal Renal Function

Trial Profile

A Single Dose, Randomized, Open-Label, Parallel Group Study Comparing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ticagrelor in Haemodialysis Patients to Subjects With Normal Renal Function

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Acute coronary syndromes; Coronary artery disease; Peripheral arterial disorders; Stroke
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Jun 2016 Status changed from recruiting to completed.
    • 02 Sep 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2016 to 1 May 2016.
    • 02 Sep 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Mar 2016 to 1 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top